Valuation: AC Immune SA

Market Cap 179M 220M 191M 164M 309M 20.99B 315M 2.11B 825M 10.47B 827M 809M 34.53B P/E 2026 *
-6.16x
P/E 2027 * 9.98x
Enterprise Value 134M 165M 143M 123M 232M 15.73B 236M 1.58B 618M 7.84B 620M 606M 25.87B EV / Sales 2026 *
3.69x
EV / Sales 2027 * 2.23x
Free-Float
56.09%
Yield 2026 *
-
Yield 2027 * -
1 day+1.37%
1 week-3.48%
Current month+1.37%
1 month-11.55%
3 months-25.50%
6 months-33.53%
Current year-29.30%
1 week 2.18
Extreme 2.18
2.4
1 month 2.12
Extreme 2.12
2.63
Current year 2.1
Extreme 2.095
3.9
1 year 2.03
Extreme 2.03
4
3 years 1.43
Extreme 1.4299
5.14
5 years 1.43
Extreme 1.4299
12.61
10 years 1.43
Extreme 1.4299
19.97
Manager TitleAgeSince
Chief Executive Officer 64 2026-06-10
Director of Finance/CFO 37 2021-12-31
Chief Tech/Sci/R&D Officer 45 2012-12-31
Director TitleAgeSince
Director/Board Member 70 2018-12-31
Director/Board Member 72 2020-11-19
Director/Board Member 65 2021-10-28
Change 5-day change 1-year change 3-year change Capi.($)
+1.37%-3.48%+4.72%-23.18% 220M
-0.44%+13.80%+35.85%-1.58% 75.81B
+1.99%-9.47%+22.66%+184.69% 48.57B
-4.18%+42.30%+42.30%+42.30% 46.01B
+3.64%+7.79%-51.37%-51.41% 41.66B
-0.56%+0.84%+52.95%-24.62% 29.82B
-0.91%-0.37%+56.67%+82.26% 24.01B
+0.58%-0.88%+99.75%-49.85% 22.01B
+0.64%-4.00%-7.10%+163.11% 19.09B
+0.39%-6.03%+64.90%+113.10% 15.83B
Average +0.26%-1.11%+32.13%+43.48% 32.3B
Weighted average by Cap. +0.08%+0.94%+29.88%+42.40%

Financials

2026 *2027 *
Net sales 36.27M 44.7M 38.85M 33.3M 62.78M 4.26B 63.87M 428M 167M 2.12B 168M 164M 7.01B 87.76M 108M 94M 80.56M 152M 10.31B 155M 1.03B 405M 5.14B 406M 397M 16.96B
Net income -30.36M -37.41M -32.51M -27.87M -52.55M -3.57B -53.46M -358M -140M -1.78B -141M -137M -5.87B 17.54M 21.62M 18.79M 16.1M 30.36M 2.06B 30.89M 207M 81M 1.03B 81.19M 79.4M 3.39B
Net Debt -44.8M -55.21M -47.99M -41.13M -77.55M -5.26B -78.9M -528M -207M -2.62B -207M -203M -8.66B 17.1M 21.07M 18.32M 15.7M 29.6M 2.01B 30.12M 202M 78.97M 1B 79.16M 77.41M 3.3B
Logo AC Immune SA
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Employees
106
Date Price Change Volume
26-08-03 US$2.220 +1.37% 118,334
26-07-31 US$2.190 -7.59% 228,984
26-07-30 US$2.370 +4.41% 245,777
26-07-29 US$2.270 -2.16% 61,335
26-07-28 US$2.320 +0.87% 104,138
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.801CHF
Average target price
6.956CHF
Spread / Average Target
+286.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACIU Stock